Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty

The purpose of my doctoral thesis was to compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy with intensity-modulated radioterapy (IMRT) to 78 Gy and IMRT using simultaneus integrated boost to 82 Gy. Ninety-four patients treated with conformal radi...

Full description

Bibliographic Details
Main Author: Doležel, Martin
Other Authors: Odrážka, Karel
Format: Doctoral Thesis
Language:Czech
Published: 2010
Online Access:http://www.nusl.cz/ntk/nusl-299729
id ndltd-nusl.cz-oai-invenio.nusl.cz-299729
record_format oai_dc
spelling ndltd-nusl.cz-oai-invenio.nusl.cz-2997292021-02-26T05:19:41Z Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty Simultaneous integrated boost in the treatment of localized prostate cancer Doležel, Martin Odrážka, Karel Šlampa, Pavel Kovařík, Josef The purpose of my doctoral thesis was to compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy with intensity-modulated radioterapy (IMRT) to 78 Gy and IMRT using simultaneus integrated boost to 82 Gy. Ninety-four patients treated with conformal radiotherapy to the prostate and base of seminal vesicles to 74 Gy represented the first group. The second group consisted of 138 patients irradiated with IMRT covering the prostate and base of seminal vesicles to 78 Gy. The last group was treated with IMRT using simultaneus integrated boost. The prescribed doses were 82 Gy and 73. 8 Gy in 42 fractions to prostate and to seminal vesicles. Late toxicity was prospectively scored according to the RTOG/FC-LENT scale. Acute gastrointestinal toxicity Grade 2 or greater occured in 35.1% patients treated with 3D-CRT, 16% with IMRT 78 and 7.7% using IMRT/SIB 82. Acute urogenital toxicity Grade 2 or greater was presented in 26.6% (3D-CRT), 33% (IMRT 78) and 30.7% (IMRT/SIB 82). At 3 years, the estimated cumulative incidence of Grade 3 late gastrointestinal toxicity was 14% for 3D-CRT, 5% for IMRT 78 and 2% for IMRT/SIB 82. The difference became significant (log rank p=0.02). The estimated cumulative incidence of Grade 3 late urogenital toxicity was 9% (3D-CRT), 7%... 2010 info:eu-repo/semantics/doctoralThesis http://www.nusl.cz/ntk/nusl-299729 cze info:eu-repo/semantics/restrictedAccess
collection NDLTD
language Czech
format Doctoral Thesis
sources NDLTD
description The purpose of my doctoral thesis was to compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy with intensity-modulated radioterapy (IMRT) to 78 Gy and IMRT using simultaneus integrated boost to 82 Gy. Ninety-four patients treated with conformal radiotherapy to the prostate and base of seminal vesicles to 74 Gy represented the first group. The second group consisted of 138 patients irradiated with IMRT covering the prostate and base of seminal vesicles to 78 Gy. The last group was treated with IMRT using simultaneus integrated boost. The prescribed doses were 82 Gy and 73. 8 Gy in 42 fractions to prostate and to seminal vesicles. Late toxicity was prospectively scored according to the RTOG/FC-LENT scale. Acute gastrointestinal toxicity Grade 2 or greater occured in 35.1% patients treated with 3D-CRT, 16% with IMRT 78 and 7.7% using IMRT/SIB 82. Acute urogenital toxicity Grade 2 or greater was presented in 26.6% (3D-CRT), 33% (IMRT 78) and 30.7% (IMRT/SIB 82). At 3 years, the estimated cumulative incidence of Grade 3 late gastrointestinal toxicity was 14% for 3D-CRT, 5% for IMRT 78 and 2% for IMRT/SIB 82. The difference became significant (log rank p=0.02). The estimated cumulative incidence of Grade 3 late urogenital toxicity was 9% (3D-CRT), 7%...
author2 Odrážka, Karel
author_facet Odrážka, Karel
Doležel, Martin
author Doležel, Martin
spellingShingle Doležel, Martin
Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty
author_sort Doležel, Martin
title Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty
title_short Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty
title_full Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty
title_fullStr Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty
title_full_unstemmed Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty
title_sort využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty
publishDate 2010
url http://www.nusl.cz/ntk/nusl-299729
work_keys_str_mv AT dolezelmartin vyuzitisimultannihointegrovanehoboostuvlecbelokalizovanehokarcinomuprostaty
AT dolezelmartin simultaneousintegratedboostinthetreatmentoflocalizedprostatecancer
_version_ 1719379576205869056